COVID-19 nasal spray from Eureka Therapeutics protects mice against infection

SARS-CoV-2, the novel coronavirus that causes COVID-19, is mainly transmitted through infective airborne droplets and tiny particles. So the respiratory airway, as the primary entry point of the virus, could be a good target for delivery of drugs aimed at protecting people against the disease.

That’s the logic behind the development of a human monoclonal antibody by Eureka Therapeutics. Now, the company has reported promising results in mice.